Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy

Aberrant activity of oncogenic rat sarcoma virus (RAS) protein promotes tumor growth and progression. RAS-driven cancers comprise more than 30% of all human cancers and are refractory to frontline treatment strategies. Since direct targeting of RAS has proven challenging, efforts have been centered...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatli, Ozge, Dinler Doganay, Gizem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703923/
https://www.ncbi.nlm.nih.gov/pubmed/34946644
http://dx.doi.org/10.3390/molecules26247561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703923/
https://www.ncbi.nlm.nih.gov/pubmed/34946644
http://dx.doi.org/10.3390/molecules26247561

Ejemplares similares